Project Grant R01AG083580
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Rochester provides $308,000 in funding to develop and pilot test a shared decision-making (SDM) tool for surgeons to use when discussing major colorectal surgery with frail older adult patients. The goal is to improve communication and decision-making in this vulnerable patient population that experiences higher complication rates and impacts to quality of life from such...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $393,750 Project Grant to the University of California, Los Angeles (UCLA) on September 22, 2025, under the Aging Research program (CFDA 93.866). This prospective cohort study aims to evaluate how aggressive cancer treatments—including systemic chemotherapy, chemoradiotherapy, and immunotherapy—impact physical function in older adults (aged 60+) with gastroesophageal cancer. The research will deliver...
- This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will fund a study to evaluate the impact of social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) diagnosis, treatment delays, and survival, with a focus on underserved populations in Kentucky and Georgia. The $192,610 award will support a 2-year epidemiologic study that aims to elucidate the relationship between SDOH measures and...
- Federal Grant Award Summary The National Institute on Aging awarded a $423,750 Project Grant to Weill Medical College of Cornell University on August 15, 2025, under the Aging Research program (CFDA 93.866) to investigate the impact of biological age on surgical outcomes. The research will deliver a comprehensive analysis examining how preoperative biological age—specifically immunologic age and metabolic age—predicts one-year postoperative mortality and loss of independence following surgery in...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $624,000.00 to the University of Texas Health Science Center at Houston to explore a patient priorities care framework for improving breast cancer survivorship care for older women with multiple chronic conditions. The project aims to use this framework to identify patient priorities, incorporate them into treatment plans, and evaluate the feasibility and impact on treatment burden and quality...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded Medstar Health Research Institute Inc. a Cooperative Agreement valued at $1,351,734 on July 25, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to deliver practical geriatric assessment services in community oncology settings. The primary objective is to increase the implementation and utilization of geriatric assessment protocols among older cancer patients (age 65+) in community-based...
- The Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $811,443 to Beth Israel Deaconess Medical Center, Inc. to conduct a cluster randomized trial of a breast cancer treatment decision aid for women aged 70 and older with low-risk stage I breast cancer. The project aims to develop and evaluate a shared decision-making training program for breast surgeons and a decision aid to inform women over 70 about the benefits and harms of their treatment...
- Federal Project Grant Award Summary Mayo Clinic Arizona has been awarded $420,000 in project grant funding from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 15, 2025, through August 31, 2027. The award funds a longitudinal research study examining quality of life (QOL) and patient priorities among older adults with indolent non-Hodgkin lymphoma (INHL). The study will leverage an existing lymphoma cohort and direct patient narratives to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $1.72M Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2025, through April 30, 2030. This award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and poor prognosis. The study will utilize the EPIC...
- This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...
GERIATRIC ASSESSMENT DOMAINS IN RELATION TO TREATMENT OUTCOMES AMONG OLDER ADULTS WITH COLORECTAL CANCER - PROJECT ABSTRACT. ABOUT 75% OF THE NEWLY DIAGNOSED COLORECTAL CANCER PATIENTS ARE 70 YEARS OLD AND HAVE THE LOWEST 5-YEAR RELATIVE SURVIVAL (61%) DUE TO COMORBIDITY AND FRAILTY. CURRENT CLINICAL CARE GUIDELINES FOR OLDER CANCER PATIENTS ONLY PARTIALLY ADDRESS SPECIFIC CHALLENGES EXPERIENCED BY THEM, THUS RESULTING IN LARGE VARIATIONS AND INCONSISTENCY IN THEIR STANDARD CANCER CARE. EVIDENCE SURROUNDING COMPLICATIONS AFTER COLORECTAL CANCER SURGERY, TREATMENT TOXICITY, AND THEIR IMPACT ON PATIENTS' QUALITY OF LIFE (QOL) IN OLDER COLORECTAL CANCER PATIENTS IS INCONSISTENT, AND RELIES HEAVILY ON THE CHRONOLOGICAL AGE OF THE PATIENT. THUS, THERE IS AN URGENT UNMET NEED TO EVALUATE PREDICTORS OF CLINICAL AND PATIENT-REPORTED OUTCOMES IN OLDER COLORECTAL CANCER PATIENTS IN ORDER TO AID CLINICAL DECISION-MAKING AND TAILOR TREATMENT REGIMENS THAT COINCIDE WITH PATIENTS' LEVEL OF RISK, WHILE MINIMIZING COMPLICATIONS AND TOXICITIES, AND IMPROVING QOL. THE CURRENT PROJECT IS PREPARED IN RESPONSE TO NIH NOSI NOT-CA-21-031, AND WILL HELP INFORM THE ROLE OF AGING-RELATED FUNCTIONAL DECLINE ON VARIOUS CLINICAL AND QOL OUTCOMES IN CANCER PATIENTS. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO EVALUATE WHETHER PHYSICAL FUNCTION (AIM 1), A MULTIDIMENSIONAL BRIEF GERIATRIC ASSESSMENT TOOL (AIM 2), AND PRE-OPERATIVE BIOMARKERS OF AGING (TELOMERE LENGTH, MITOCHONDRIAL DNA COPY NUMBER), INFLAMMATION, NUTRITIONAL STATUS AND A BIOLOGICAL AGING SCORE (AIM 3) ARE ASSOCIATED WITH POSTSURGICAL COMPLICATIONS, TREATMENT TOXICITY, SURVIVAL, QOL, AND COGNITIVE OUTCOMES IN GERIATRIC COLORECTAL CANCER PATIENTS. OUR CENTRAL HYPOTHESIS IS THAT OUTCOMES IN GERIATRIC COLORECTAL CANCER PATIENTS ARE ASSOCIATED WITH PHYSICAL, FUNCTIONAL, EMOTIONAL, AND COGNITIVE STATUS, IRRESPECTIVE OF PATIENTS' CHRONOLOGICAL AGE. WE PROPOSE TO RECRUIT A PROSPECTIVE COHORT OF NEWLY DIAGNOSED STAGE I-III COLORECTAL CANCER PATIENTS (N~462) 70 YEARS OF AGE RECRUITED ~2 WEEKS PRIOR TO THEIR CANCER SURGERY. AT STUDY ENROLLMENT, WE WILL ASSESS PATIENTS' PHYSICAL FUNCTION THROUGH SHORT PHYSICAL PERFORMANCE BATTERY AND HANDGRIP TESTING, AND ADMINISTER A BRIEF GERIATRIC ASSESSMENT TOOL DEVELOPED BY HURRIA ET. AL. BIOMARKERS OF BIOLOGICAL AGING, INFLAMMATION, AND NUTRITIONAL STATUS WILL BE MEASURED IN STORED BLOOD COLLECTED PRIOR TO SURGERY USING WELL-VALIDATED ASSAYS. ASSOCIATIONS OF THESE EXPOSURES WITH SURGICAL COMPLICATIONS (AT 30 DAYS), TREATMENT TOXICITY, QOL AND COGNITIVE FUNCTION (AT 12 MONTHS), AND CLINICAL OUTCOMES SUCH AS SURVIVAL (AT 24 MONTHS) WILL BE MEASURED. OUR PROPOSED STUDY DESIGN IS COST-EFFECTIVE AS IT BUILDS UPON A WELL-ESTABLISHED UNIQUE COHORT CURRENTLY RECRUITING COLORECTAL CANCER PATIENTS
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $62.0k | 6/10/25 | ||
| Not listed | $697.3k | 3/20/25 | ||
| Not listed | $697.3k | 3/20/25 | ||
| Not listed | $802.9k | 7/5/24 | ||
| Not listed | $802.9k | 7/5/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
1006990103HLMS | H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. | Project Grant R01AG083580 | $364.1k | 3/7/25 | |
1006990101UTHSCS | University Of Tennessee | Project Grant R01AG083580 | $83.6k | 1/13/25 | |
1006990102WUS | The Washington University | Project Grant R01AG083580 | $241.9k | 1/2/25 |